In this rapid-fire roundtable session, Clinical Lipid Specialists Joyce Ross, MSN, CRNP and Dr. Lynne Braun PhD, CNP discuss PCSK9 Inhibitors in practice, including the latest data from CV outcomes studies. They demonstrate how these trials will impact practice through dynamic case studies, including a patient’s with diabetic dyslipidemia, ASCVD, and familial hypercholesterolemia.

Reducing LDL-C with Non-Statin Therapies Lipid specialists Drs. Lynne Braun and Michael Miller discuss the importance of LDL cholesterol management for prevention and management of atherosclerotic cardiovascular disease (ASCVD). The role of non-statin therapies including emerging evidence with PCSK9 inhibition on major CV outcomes is presented in this dynamic presentation.

Improve Access to New LDL-C Therapies Learn current strategies for managing high-risk dyslipidemia including the use of PCSK9 Inhibitors. Case studies in familial hyperlipidemia demonstrate the application of lipid-lowering therapies in practice.